cognitive impairment
Conditions
Interventions
Subjects will receive a daily dose of 3.5g rumenic acid divided over six capsules (intervention) or six placebo capsules (control).
Sponsors
Stepan Specialty Products B.V.
Eligibility
Inclusion criteria
Inclusion criteria: • Aged =65 years • At risk of cognitive impairment/ memory complaints • Able to understand and perform the study procedures
Exclusion criteria
Exclusion criteria: • Body Mass Index (BMI) >35 kg/m2 • Current use of medication belonging to the “sartans” or “glitazones” • Current use of >500 mg/day of acetylsalicylic acid • Current use of medication that affects inflammation (anti-inflammatory medication) • Fish consumption of more than 1 serving per week • Current or recent (<1 month) use of fish oil supplements • Current or recent (<1 month) use of anti-inflammatory dietary supplements such as quercetin, curcumin, resveratrol, and/or other flavonoids • Diabetes mellitus • Having a disease which interferes with the effect of the RAR-CLA supplement and/or with the outcome measure (cognitive functioning) as judged by medical doctor • Swallowing problems • Current participation in other scientific research with the exception of EetMeetWeet!
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Episodic memory as measured with the RAVLT | — |
Secondary
| Measure | Time frame |
|---|---|
| cognitive functioning (episodic and working memory, attention, executive functioning, and psychomotor speed) as measured with a battery of cognitive tests, the evaluation of rumenic acid supplementation on anxiety, depressive symptoms, quality of life (measured with questionnaires), and plasma fatty acid status (measured in blood) | — |
Contacts
Public ContactOndine van de Rest
Wageningen University & Research
Outcome results
None listed